BioSpace News Archive

CathVision today announced an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics.

The Insight Partners published latest research report on “Gastrointestinal Drugs Market Sales Report, Size, Share, Trends, Growth and Demand Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution Channel and Geography” the global market size is projected to reach USD 71,300.28 million by 2027 from USD 49,043.38 million in 2019;

Regulatory News: POXEL SA announced TWYMEEG® Fiscal Year and fourth quarter 2022 results, as recently published by Sumitomo Pharma, its partner commercializing TWYMEEG in Japan.

Clinical ink, a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.

Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced a worldwide milestone achievement with the 9,000th patient receiving the Optimizer® system for the treatment of moderate HF.

Battelle has honored Kavitha Dasu as the 2022 Inventor of the Year. Three years ago, Dasu was honored with Battelle’s Emerging Scientist award.

Koning Corporation, the leading manufacturer of breast computed tomography systems, announced that it has received the largest pipeline of orders in its history.

Castle Biosciences, Inc. today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh annual MedTech Breakthrough Awards program for its innovative TissueCypher® Barrett’s Esophagus test.

PDS Biotechnology Corporation, a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.